Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies
- 22 October 2019
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Cardiology
- Vol. 140 (17), 1366-1368
- https://doi.org/10.1161/circulationaha.119.040680
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery DiseaseJournal of the American College of Cardiology, 2019
- Restricted Mean Survival Time as a Measure to Interpret Clinical Trial ResultsJAMA Cardiology, 2017
- Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trialThe Lancet, 2016
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority StudiesAnnals of Internal Medicine, 2015
- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeThe Lancet, 2003